<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04401865</url>
  </required_header>
  <id_info>
    <org_study_id>PXL-330</org_study_id>
    <nct_id>NCT04401865</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of the PXL-Platinum 330 System</brief_title>
  <official_title>Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Colorado Eye Consultants/Cornea Consultants of Colorado</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Colorado Eye Consultants/Cornea Consultants of Colorado</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the PXL Platinum 330 system for performing
      corneal cross-linking (CXL) for the treatment of ectatic disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with progressive keratoconus, pellucid marginal degeneration, or at risk for
      post-refractive corneal ectasia will be recruited and undergo epithelial-on corneal
      crosslinking with the Peschke PXL-330 system using pulsed, accelerated energy delivery.
      Patients will undergo monitoring for 1 year, with serial measurements of corneal topography,
      visual acuity, intraocular pressure, and pachymetry.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 26, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corrected distance visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Change in corrected distance visual acuity (CDVA) at the last required study visit (6 months post-op), compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uncorrected visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Change in UCVA at 6 months, compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Keratometry</measure>
    <time_frame>12 months</time_frame>
    <description>Change in Kmax, compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Corneal Ectasia</condition>
  <condition>Keratoconus</condition>
  <condition>Pellucid Marginal Corneal Degeneration</condition>
  <arm_group>
    <arm_group_label>Pulsed, Accelerated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mW, 10 sec on, 10 sec off, 24 minutes of illumination Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mW, 10 sec on, 10 sec off, 30 minutes of illumination Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>PXL-330 Platinum device for crosslinking with Peschke riboflavin solution</intervention_name>
    <description>Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea</description>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_label>Pulsed, Accelerated</arm_group_label>
    <other_name>Corneal cross-linking</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of keratoconus, forme fruste keratoconus, post-LASIK ectasia, pellucid
             marginal degeneration, forme fruste pellucid marginal degeneration, history of radial
             keratotomy with fluctuating vision, Terrien's marginal degeneration.

          2. Must have provided informed consent, documented it in writing, and have been given a
             copy of the signed informed consent form.

          3. Must be willing and able to return for scheduled treatment and follow-up examinations
             for the duration of the study.

          4. Must be at least 8 years of age.

          5. Non-consenting/impaired individuals with a LAR's signature

        Exclusion Criteria:

          1. Corneal thickness &lt; 300 microns measured by ultrasound or Pentacam.

          2. Contraindications or sensitivities to any study medications or their components.

          3. Pregnancy or breastfeeding.

          4. Any history of Herpes simplex corneal disease in an eye to be treated.

          5. Nystagmus or any other condition that would, in the judgement of the investigator,
             prevent a steady gaze during the treatment.

          6. Inability to cooperate with diagnostic tests.

          7. Current enrollment in another ophthalmic clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Lance Forstot, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Colorado Eye Consultants/Corneal Consultants of Colorado</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melanie Fortin, MSBS</last_name>
    <phone>720-709-7523</phone>
    <email>mfortin@corneaonline.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wendy Bigger</last_name>
    <phone>720-709-7533</phone>
    <email>wbigger@corneaonline.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Colorado Eye Consultants/Corneal Consultants of Colorado</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Fortin, MSBS</last_name>
      <phone>720-709-7523</phone>
      <email>mfortin@corneaonline.com</email>
    </contact>
    <contact_backup>
      <last_name>Wendy Bigger</last_name>
      <phone>720-709-7533</phone>
      <email>wbigger@corneaonline.com</email>
    </contact_backup>
    <investigator>
      <last_name>S. Lance Forstot, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert I Fish, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bradley Gustave, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael T Wildes, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chicago Cornea Consultants, Ltd.</name>
      <address>
        <city>Highland Park</city>
        <state>Illinois</state>
        <zip>60035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jim Nykaza</last_name>
      <phone>847-748-3553</phone>
      <email>jimn@chicagocornea.com</email>
    </contact>
    <investigator>
      <last_name>Rachel Epstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Randy Epstein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Parag Majmudar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Eye Clinic</name>
      <address>
        <city>Brecksville</city>
        <state>Ohio</state>
        <zip>44141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Kus-Kreidler</last_name>
      <phone>216-503-6535</phone>
      <email>ekus-kreidler@clevelandeyeclinic.com</email>
    </contact>
    <investigator>
      <last_name>Shamik Bafna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Wiley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathleen Jee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Augustine, OD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kayla Karpuk, OD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

